Thus, because LSD1 is upregulated in various cancers, including breast and prostate, and there is preliminary evidence of LSD1-dependent BRCA1 suppression and PARP inhibitor sensitivity, further clinical validation is required to explore LSD1 as an official biomarker for responsiveness to PARP inhibitor. The gene discussed is BRCA1; the disease is cancer.